Table 1.
Baseline characteristics of patients with and without AHRE
| Overall (n = 856) | AHRE (n = 125) | No AHRE (n = 731) | P value | |
|---|---|---|---|---|
| Demographics | ||||
| Age, median (IQR) | 72.0 (62.0–80.0) | 74 (63.0–81.0) | 71.0 (62.0–79.0) | 0.03 |
| Age 65–74 y | 232 (27.1) | 29 (23.2) | 203 (27.8) | 0.29 |
| Age > 75 y | 383 (44.7) | 66 (52.8) | 317 (43.4) | 0.05 |
| Female gender [no., (%)] | 336 (39.3) | 342 (33.6) | 294 (40.2) | 0.16 |
| BMI, median (IQR) | 27.9 (24.6–31.7) | 27.4 (23.5–31.8) | 28.0 (24.6–31.5) | 0.41 |
| Medical history [no., (%)] | ||||
| Hypertension | 603 (70.4) | 91 (72.8) | 512 (70.0) | 0.53 |
| Diabetes mellitus | 241 (28.2) | 36 (28.8) | 205 (28.0) | 0.86 |
| Dyslipidemia | 554 (68.6) | 81 (68.6) | 473 (68.7) | 1.00 |
| Heart failure | 214 (25.0) | 39 (31.2) | 175 (23.9) | 0.08 |
| Prior stroke/TIA | 92 (10.7) | 15 (12.0) | 77 (10.5) | 0.63 |
| Vascular disease | 317 (37.0) | 48 (38.4) | 269 (36.8) | 0.73 |
| Prior history of AF | 212 (24.8) | 75 (60.0) | 137 (18.7) | < 0.001 |
| Thromboembolic risk, mean ± SD | ||||
| CHADS2 score | 1.9 ± 1.2 | 2.0 ± 1.3 | 1.9 ± 1.2 | 0.07 |
| CHA2DS2-VASc score | 3.4 ± 1.6 | 3.5 ± 1.7 | 3.3 ± 1.6 | 0.22 |
| Medications [no., (%)] | ||||
| Beta-blocker | 270 (35.5) | 47 (40.9) | 223 (34.5) | 0.19 |
| ACE-I/ARB | 436 (56.7) | 66 (57.4) | 370 (56.6) | 0.87 |
| Diuretics | 276 (35.8) | 42 (36.5) | 234 (35.7) | 0.87 |
| Statin | 509 (66.0) | 74 (64.3) | 435 (66.3) | 0.68 |
| OAC | 151 (19.7) | 54 (47.0) | 97 (14.9) | < 0.001 |
| Antiplatelet | 396 (51.4) | 49 (42.2) | 347 (53.0) | 0.03 |
| Digoxin | 38 (4.9) | 12 (10.4) | 26 (4.0) | 0.003 |
ACE-I angiotensin-converting enzyme inhibitor, AF atrial fibrillation, AHRE atrial high rate episode, ARB angiotensin II receptor blocker, BMI body mass index, IQR interquartile range, OAC oral anticoagulant, TIA transient ischemic attack